Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine versus treatment choice in previously treated acute myeloid leukemia
2015-005256-97Phase 3Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of guadecitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Astex Pharmaceuticals. Primary endpoint: Overall survival. Started Mar 2017; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-005256-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005256-97.